Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of IVX-A12 RSV and hMPV VLP Vaccine in Adults ≥60 Years
2024-513740-28-00Phase 3Authorised
- Sponsor
- AstraZeneca
- Start
- Nov 2024
- Modality
- Vaccines & Immunotherapeutics, Nanoparticles → Drug Delivery Systems
- Countries
- 26
01
Overview
Phase 3, randomised, double-blind trial in respiratory syncytial virus disease (RSV), human metapneumovirus infection (HMPV) and pulmonary infection comparing IVX-A12 vaccine with Placebo (2 arms). Primary endpoints: RSV-confirmed LRTD incidence first season and hMPV-confirmed LRTD incidence first season. Planned start Nov 2024; status: authorised.
02
Drugs
IVX-A12
03
Conditions
respiratory syncytial virus disease (RSV)human metapneumovirus infection (HMPV)pulmonary infection
Beyond the preview
Go deeper on 2024-513740-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513740-28-00.